View Older Stories View More Recent Stories

Jul 20, 2023 08:05AM Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
Jul 12, 2023 04:05PM Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023
Jul 5, 2023 08:05AM Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
May 31, 2023 08:05AM Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
May 29, 2023 09:00PM Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
May 17, 2023 08:05AM Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
May 16, 2023 08:00AM Guardant Health Releases Inaugural ESG Report
May 9, 2023 10:15AM Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
May 8, 2023 04:05PM Guardant Health Announces Additions to Leadership Team
May 5, 2023 08:00AM Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
Apr 27, 2023 04:05PM Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
Apr 25, 2023 08:05AM Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
Apr 21, 2023 08:05AM Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
Apr 19, 2023 04:05PM Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
Apr 18, 2023 08:05AM Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
Apr 11, 2023 08:05AM Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
Mar 21, 2023 08:05AM Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
Mar 10, 2023 08:05AM Guardant Health (GH) submits premarket approval application to the U.S. Food and Drug Administration for Shield blood test
Mar 10, 2023 08:05AM Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
Feb 27, 2023 04:06PM Guardant Health (GH) Appoints Musa Tariq to its Board
Feb 27, 2023 04:05PM Musa Tariq Joins Guardant Health Board of Directors
Feb 17, 2023 08:00AM Guardant Health to Participate in Upcoming March Investor Conferences
Feb 15, 2023 08:05AM Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
Feb 8, 2023 08:05AM Guardant Health (GH) receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
Feb 8, 2023 08:05AM Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
Feb 2, 2023 08:06AM Guardant Health (GH) and AnHeart Collaborate to Develop Guardant360 CDx and Guardant360 TissueNext
Feb 2, 2023 08:05AM Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Pos
Feb 2, 2023 06:00AM Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
Feb 1, 2023 04:05PM Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Jan 31, 2023 08:05AM Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
Jan 30, 2023 07:07AM Guardant Health (GH) Granted FDA Approval for Guardant360 CDx
Jan 30, 2023 07:05AM Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic
Jan 19, 2023 08:05AM Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
Jan 17, 2023 04:05PM Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
Dec 28, 2022 08:00AM Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Dec 21, 2022 08:05AM Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
Dec 15, 2022 04:16PM Guardant Health (GH) Reports Positive ECLIPSE Trial Results
Dec 15, 2022 04:16PM Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
Dec 8, 2022 04:05PM Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer
Dec 1, 2022 08:05AM Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
Oct 10, 2022 04:05PM Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
Sep 9, 2022 04:30PM Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
Sep 6, 2022 08:05AM Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
Aug 31, 2022 08:05AM Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
Aug 29, 2022 04:05PM Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
Aug 15, 2022 08:05AM Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
Aug 12, 2022 08:07AM Guardant Health (GH) Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for for ENHERTU
Aug 12, 2022 08:05AM Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
Aug 8, 2022 06:15AM Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
Aug 5, 2022 08:05AM Guardant Health (GH) Reports New Data from its Portfolio of Blood Tests and GuardantINFORM Platform
View More Recent Stories View Older Stories